Combination therapy with interferon and JAK1-2 inhibitor is feasible: Proof of concept with rapid reduction in JAK2V617F-allele burden in polycythemia vera

M. E. Bjørn; K. de Stricker; L. Kjær; K. Ellemann; H. C. Hasselbalch

doi:10.1016/j.lrr.2014.05.003

Combination therapy with interferon and JAK1-2 inhibitor is feasible: Proof of concept with rapid reduction in JAK2V617F-allele burden in polycythemia vera

M. E. Bjørn^*, K. de Stricker, L. Kjær, K. Ellemann, H. C. Hasselbalch

^*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskrift › Artikel › Forskning › peer review

Abstract

We report a 55 year old woman with post-ET PV for 12 years, who experienced resolution of severe constitutional symptoms within 3 days, a marked reduction in splenomegaly and a rapid decline in the JAK2V617F allele burden during combination therapy with interferon-alpha2a and ruxolitinib. Within 4 weeks the patient achieved complete hematological remission with normalization of peripheral blood counts and within 10 months the JAK2V617F-allele burden was reduced from 90% to 28%. Such a rapid decline in the JAK2V617F allele burden is highly unusual in PV-patients during low-dose IFN-alpha2 monotherapy and this finding warrants a prospective study with combination therapy.

Originalsprog	Engelsk
Sider (fra-til)	73-75
Antal sider	3
Tidsskrift	Leukemia Research Reports
Vol/bind	3
Udgave nummer	2
DOI	https://doi.org/10.1016/j.lrr.2014.05.003
Status	Udgivet - 1 aug. 2014

Adgang til dokumentet

10.1016/j.lrr.2014.05.003

Andre filer og links

http://www.scopus.com/inward/record.url?scp=84920858525&partnerID=8YFLogxK

1 Kommentar/debat

Corrigendum to "Combination therapy with interferon and JAK1-2 inhibitor is feasible. Proof of concept with rapid reduction in JAK2V617F-allele burden in Polycythemia Vera" [Leuk. Res. Rep. 3 (2) (2014) 73-75]
Bjørn, M. E., de Stricker, K., Kjær, L., Ellemann, K. & Hasselbalch, H. C., 1 dec. 2015, I: Leukemia Research Reports. 4, 1, 1 s.
Publikation: Bidrag til tidsskrift › Kommentar/debat › Forskning

Åben adgang

Citationsformater

@article{e409ec5e385f44159d147ead51983bed,

title = "Combination therapy with interferon and JAK1-2 inhibitor is feasible: Proof of concept with rapid reduction in JAK2V617F-allele burden in polycythemia vera",

abstract = "We report a 55 year old woman with post-ET PV for 12 years, who experienced resolution of severe constitutional symptoms within 3 days, a marked reduction in splenomegaly and a rapid decline in the JAK2V617F allele burden during combination therapy with interferon-alpha2a and ruxolitinib. Within 4 weeks the patient achieved complete hematological remission with normalization of peripheral blood counts and within 10 months the JAK2V617F-allele burden was reduced from 90% to 28%. Such a rapid decline in the JAK2V617F allele burden is highly unusual in PV-patients during low-dose IFN-alpha2 monotherapy and this finding warrants a prospective study with combination therapy.",

keywords = "Combination therapy, Interferon, JAK2V617F-allele burden, Polycythemia vera, Ruxolitinib",

author = "Bj{\o}rn, {M. E.} and {de Stricker}, K. and L. Kj{\ae}r and K. Ellemann and Hasselbalch, {H. C.}",

year = "2014",

month = aug,

day = "1",

doi = "10.1016/j.lrr.2014.05.003",

language = "English",

volume = "3",

pages = "73--75",

journal = "Leukemia Research Reports",

issn = "2213-0489",

publisher = "Elsevier",

number = "2",

}

TY - JOUR

T1 - Combination therapy with interferon and JAK1-2 inhibitor is feasible

T2 - Proof of concept with rapid reduction in JAK2V617F-allele burden in polycythemia vera

AU - Bjørn, M. E.

AU - de Stricker, K.

AU - Kjær, L.

AU - Ellemann, K.

AU - Hasselbalch, H. C.

PY - 2014/8/1

Y1 - 2014/8/1

N2 - We report a 55 year old woman with post-ET PV for 12 years, who experienced resolution of severe constitutional symptoms within 3 days, a marked reduction in splenomegaly and a rapid decline in the JAK2V617F allele burden during combination therapy with interferon-alpha2a and ruxolitinib. Within 4 weeks the patient achieved complete hematological remission with normalization of peripheral blood counts and within 10 months the JAK2V617F-allele burden was reduced from 90% to 28%. Such a rapid decline in the JAK2V617F allele burden is highly unusual in PV-patients during low-dose IFN-alpha2 monotherapy and this finding warrants a prospective study with combination therapy.

AB - We report a 55 year old woman with post-ET PV for 12 years, who experienced resolution of severe constitutional symptoms within 3 days, a marked reduction in splenomegaly and a rapid decline in the JAK2V617F allele burden during combination therapy with interferon-alpha2a and ruxolitinib. Within 4 weeks the patient achieved complete hematological remission with normalization of peripheral blood counts and within 10 months the JAK2V617F-allele burden was reduced from 90% to 28%. Such a rapid decline in the JAK2V617F allele burden is highly unusual in PV-patients during low-dose IFN-alpha2 monotherapy and this finding warrants a prospective study with combination therapy.

KW - Combination therapy

KW - Interferon

KW - JAK2V617F-allele burden

KW - Polycythemia vera

KW - Ruxolitinib

UR - http://www.scopus.com/inward/record.url?scp=84920858525&partnerID=8YFLogxK

U2 - 10.1016/j.lrr.2014.05.003

DO - 10.1016/j.lrr.2014.05.003

M3 - Article

C2 - 25379406

AN - SCOPUS:84920858525

SN - 2213-0489

VL - 3

SP - 73

EP - 75

JO - Leukemia Research Reports

JF - Leukemia Research Reports

IS - 2

ER -

Combination therapy with interferon and JAK1-2 inhibitor is feasible: Proof of concept with rapid reduction in JAK2V617F-allele burden in polycythemia vera

Abstract

Adgang til dokumentet

Andre filer og links

Fingeraftryk

Publikation

Corrigendum to "Combination therapy with interferon and JAK1-2 inhibitor is feasible. Proof of concept with rapid reduction in JAK2V617F-allele burden in Polycythemia Vera" [Leuk. Res. Rep. 3 (2) (2014) 73-75]

Citationsformater